Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Huoxue Shengji
- Development stage
- Unknown
- Lead developer
- The Affiliated Hospital of Guangdong Medical University
- Administration
- Topical
01
Overview
Huoxue Shengji (HXSJ) is a traditional Chinese medicine (TCM) decoction primarily used for the treatment of chronic skin ulcers, including venous leg ulcers and refractory wounds. It is clinically applied to promote granulation tissue formation and accelerate wound healing. Mechanistically, HXSJ has been shown to alleviate ferroptosis in vascular endothelial cells by modulating the Nrf2/xCT/GPX4 signaling pathway, specifically preventing the inactivation of glutathione peroxidase 4 (GPX4) caused by iron accumulation. It is often used in combination with other therapies such as vacuum sealing drainage (VSD) or negative pressure wound therapy with instillation (NPWTi).
- Other names
- Huoxue Shengji decoctionHXSJ
Beyond the preview
Go deeper on Huoxue Shengji.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Huoxue Shengji.